Pharco Corporation operates 6 manufacturing subsidiaries, which cover a wide range of dosage forms including:

• Tablets
• Hard Gelatin Capsules
• Soft Gelatin Capsules
• Sachets
• Syrups
• Sprays
• Suppositories
• Drops
• Ampoules
• Powder for Oral Suspension (POS)
• Sterile Vials

Pharco Corporation has 2 separate manufacturing sites for the production of sterile and non-sterile B-Lactams:

• Penicillins are produced at Pharco Pharmaceuticals
• Cephalosporins are produced at Pharco B International

Two of Pharco Corporation's subsidiaries and production plants are GMP certified by the European Union authorities (member of PICs scheme):

Pharco Corporation can be your resource for customized finishing options. We can be your partner and help you with the following finishing possibilities:

• Diverse-volume packaging, from small to large
• Customized, labeling/packaging
• Flexible packaging configurations
• High-speed commercial production
• Bulk packaging
• Individual and bulk shipping cartons
• Blister trays (single and multiple)
• Finished products

Exports

Pharco Corporation exports to over 55 countries within the MENA region, CIS countries, South East Asia and Eastern Europe.
We are currently seeking worldwide commercial partners to import and distribute our products.

Under-licensing Services
• We are constantly seeking partners willing to enter the Egyptian market and can help you with achieving your strategic objectives and goals
• From acquiring raw materials to shipping the final packaged product, we utilize our broad reach of communication networks and distribution channels to ensure your investment is a profitable one
• Pharco Corporation's combined sales force is made of over 1400 Medical Representatives
• Innovative products are a pillar at Pharco Corporation. We can provide our international partners with the resources they require to produce them and distribute them in their respective markets
• Our patented drugs include:

• Mirazid® is a natural oleogumresin for the treatment of Schistosomiasis and Fascioliasis. Clinical trials have shown 98% cure rate with the application of the product within 3 months of treatment
• PedyPhar® is a groundbreaking new medicine for the treatment of diabetic foot ulcers. Clinical trials have shown miraculous results on patients within 2 to 6 months
• Aloreed® is a new high grade pharmaceutical drug for the treatment of psoriasis. Trials have shown more than 82% complete cure rate

• We currently have several products being developed in the pipeline including oral insulin, Hepatitis C and we are looking for partners to support us in the completion of the R&D process and later on to help us with the registration and distribution